Abstract:Ethnopharmacological relevance: The root of Scutellaria baicalensis Georgi has been used extensively in traditional Chinese medicine for the treatment of inflammation, fever, cough, dysentery, and hypertension. Baicalein is a flavonoid isolated from the root of Scutellaria baicalensis Georgi and is a novel neuroprotective agent under development for the treatment of Parkinson's disease. We aimed to investigate the pharmacokinetic (PK) properties of baicalein and its main metabolite, bacalin, after single-dose administration in healthy Chinese subjects. The safety and tolerability of baicalein were also assessed.Materials and methods: This was a Phase I, randomized, double-blind, single-dose trial of baicalein (1002800 mg) in 72 healthy adults. Samples of blood, urine and feces were collected at regular intervals up to 48 h after administration of the study drug. Baicalein and baicalin were then analyzed using liquid chromatography-tandem mass spectrometry (LC/MS/MS). The maximum concentration that the drug achieved after dosing (C-max), time to C-max (T-max), terminal half-life (t(1/2)), area under the curve from time zero to time of last quantifiable concentration (AUC((0,t))), area under the curve from time zero to infinity (AUC(0,,x,)), apparent total plasma clearance (CL/F), and apparent total volume of distribution (V/F) were determined using non-compartmental models. Dose proportion was tested using a method combining the equivalence criterion and power model. Physical examinations, vital signs, ECG findings, hematology, and urinalysis were monitored before and at regular intervals after administration of the study drug. Results: The PK profile of baicelein and baicelin was characterized by a median Tmax of 0.75-3.5 h and 0.5-3 h, respectively, followed by a multiphasic profile with a t(1/2) of 1.90-15.01 h and 4.22-10.80 h, respectively. The estimates of the proportionality coefficient (90% CI) for Cm, ADC, and AUC0_, 0 were 0.83 (0.70-0.96), 0.91 (0.81-1.00) and 0.92 (0.82-1.02), respectively. All values overlapped within the pre-specified range of (0.89-1.11), (0.93-1.07), and (0.93-1.07), respectively. Dose proportionality was inconclusive for a baicalein dose range of 100-2800 mg. The total urinary clearance of baicalein and baicalin was < 1%. Approximately 27% of baicalein was eliminated as unchanged drug in feces. Baicalein was well tolerated. Eleven treatment-related adverse events were observed, and all were rated as "mild" and resolved without further treatment. No serious adverse events occurred.Conclusions: Single oral doses of 100-2800 mg of baicalein were safe and well tolerated by healthy subjects. Clinical laboratory assessments showed no signs of toxicity in the liver or kidney. The favorable safety profile and PK properties warrant further clinical studies for baicalein. (C) 2014 Elsevier Ireland Ltd. All rights reserved.

Identification and High-Throughput Quantification of Baicalein and Its Metabolites in Plasma and Urine.

Identification of the Metabolites of Baicalein in Human Plasma

Identification and quantification of baicalein, wogonin, oroxylin A and their major glucuronide conjugated metabolites in rat plasma after oral administration of Radix scutellariae product.

Hepatic Metabolism and Disposition of Baicalein via the Coupling of Conjugation Enzymes and Transporters— In Vitro and In Vivo Evidences

UPLC-Q-TOF/MS-based Screening and Identification of the Main Flavonoids and Their Metabolites in Rat Bile, Urine and Feces after Oral Administration of Scutellaria Baicalensis Extract.

Safety, Tolerability, Pharmacokinetics, and Food Effect of Baicalein Tablets in Healthy Chinese Subjects: A Single-Center, Randomized, Double-Blind, Placebo-Controlled, Single-Dose Phase I Study.

Identification of the Metabolites of Baicalein in Rat Serum

In Vitro and in Situ Evaluation of Herb–drug Interactions During Intestinal Metabolism and Absorption of Baicalein

Safety, Tolerability, and Pharmacokinetics of a Single Ascending Dose of Baicalein Chewable Tablets in Healthy Subjects.

Simultaneous Determination Of Baicalein And Baicalin In Human Plasma By High Performance Liquid Chromatograph-Tandem Spectrometry And Its Application In A Food-Effect Pharmacokinetic Study

Progress in Pharmacokinetic Researches of Baicalein

A Metabolite of Baicalin Detected in Rabbit Plasma Using Electrospray Mass Spectrometry after Baicalin Administration

Safety, Tolerability, and Pharmacokinetics of Oral Baicalein Tablets in Healthy Chinese Subjects: A Single‐center, Randomized, Double‐blind, Placebo‐controlled Multiple‐ascending‐dose Study

Separation and Purification and Structural Characterization of Baicalein

Absorption, excretion and enterohepatic circulation of baicalein in rats

Pharmacological Effects and Pharmacokinetics Properties of Radix Scutellariae and Its Bioactive Flavones.

The comprehensive study on the therapeutic effects of baicalein for the treatment of COVID-19 in vivo and in vitro

Comparison of metabolic pharmacokinetics of baicalin and baicalein in rats

Comparison of the metabolism of baicalin in rats orally administered with Radix scutellariae extract and Shuang-Huang-Lian extract.

Simulated gastrointestinal tract metabolism and pharmacological activities of water extract of Scutellaria baicalensis roots.

Unraveling spatial metabolome of the aerial and underground parts of Scutellaria baicalensis by matrix-assisted laser desorption/ionization mass spectrometry imaging